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Within the past several years, the field of stereotactic 
radiotherapy (SRT) has seen numerous technological 
enhancements, including new dedicated devices for dose 
delivery. The one of the critical points of proper preparation 
and realization of SRT treatment is treatment planning 
process that is realized on dedicated softwares. 
The goal of this presentation is to describe the specific 
requirements during SRT treatment plan preparation for two 
different machines such as Tomotherapy and CyberKnife.  
The presentation includes aspects of: (i) the general 
properties of these machines, (ii) methods of patient 
fixations, (iii) preparation of the scans, (iv) delineation 
process, (v) the dose normalization methods, (vi) 
optimization process and finally (vii) the aspects of the 
quality of the dose distribution and their delivery using these 
machines. 
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Aim of presentation: Presentation describes the 
methodology planning and implementation of GK treatments 
and its comparison to VMAT planning for the same patient 
with diagnosed brain lesions. 
The method of stereotactic radiosurgery realised so far with 
use of GK in Katowice concerns patients with: acoustic 
neuroma, meningioma, brain metastases and also others, like 
hamartoma (first treatment in Poland) and trigeminal 
neuralgia – functional disorder.  
The total volume and number of lesions determines the time 
of patient’s irradiation (it fluctuates from minutes to hours). 
Radiosurgery procedure is a few step treatment preparing 
patients to high-dose radiation therapy in a single fraction. 
Whole procedure performed by neurosurgeon, radio-
oncologist, medical physicists and nurse, starting with 
stereotactic frame fixation throughout CT/MRI imaging, 
contouring, computer treatment planning and finally 
irradiation, are executed in the same day. Treatment 
planning is prepared in GammaPlan v.9.0 and calculations are 
based on MRI imaging. Estimation of distortion for MRI 
imaging system used to planning and calculations, is very 
important due to small volumes of treated lesions and 
proximity to critical structures. MRI distortion is de facto 
larger than GK device accuracy, so that it is always corrected 
by fusion with CT imaging. Owing to Department of 
Radiotherapy, localized in the same centre, equipped with a 
three high-energy accelerators with µMLC collimators, 
adapted to perform stereotactic methods, patients qualified 
to stereotactic radiosurgery treatment methods have a 
possibility of a comprehensive analysis and selection of 
optimal treatment, taking into account also the classical 
method of stereotactic radiotherapy. During the presentation 
examples of GK and VMAT plan will be showed and discussed. 
The advantages of GK radiosurgery are its accuracy due to 
stability of the therapeutic Co-60 sources beams formed by 
collimators with diameters: 4mm, 8mm, 14mm and 18mm, 
mechanical simplicity of the unit, frame fixation and 
extensive clinical experience (aprox. 50 years of GK use in 
clinic). 
The relative disadvantages are invasive method of frame 
fixation, time of treatment, handling of cobalt sources and 
its only intracranial possibility of use.  
In conclusion, GK is a very precise and reliable tool for 
intracranial radiosurgery and its localisation in the university 
hospital together with modern radiotherapy department 
equipped with linacs enables to find the best available 
treatment for  patients and also to expand the knowledge 
and skills of medical personel and students. 
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Purpose: The key role of PET diagnostic with the markers is a 
precise detection of a margin between tumor cells and 
surrounding tissue. The aim of this study is a demonstration 
of usefulness of incorporating (68)Ga-DOTATATE PET/CT for a 
target delineation of meningiomas treated with 
hypofractionated robotic radiotherapy using CyberKnife. 
Material and methods: Between June 2012 and December 
2014 60 meningiomas in 54 patients were qualified for 
CyberKnife radiation treatment with incorporation of (68)Ga-
DOTATATE PET/CT data. Target and OARs delineating was 
performed using T1-weighted MRI and (68)Ga- DOTATATE-
PET/CT fusion. MRI and PET/CT data was imported into 
treatment planning system and then fused. Maximum SUV 
values within every target were reported. Radiotherapy 
treatment planning was performed on MultiPlan CyberKnife 
System. A base set images for dose calculation was CT 
without contrast medium. The target volumes (PTV) were 
delineated twice, first on MRI/CT fusion and then on PET/CT 
fusion. The final contour was created as a sum of the 
previously prepared contours (Boolean OR operator). Mean 
radiation dose was 17,6±3,3 Gy (min. 5 Gy; max. 24 Gy). 
Results: Maximum SUV value was 17,0±17,6 g/ml. Mean 
volume of PTV on MRI, PET/CT and PET/CT/MRI were: 
12,4±22,1 cm3, 13,2±26,0 cm3, 17.5±24,6 cm3 respectively. In 
41 cases the PTV volume on PET/CT was larger than on MRI 
based. The largest differences were mostly pronounced in 
post operative base skull cases where it was more difficult to 
differentiate the postoperative changes from tumor tissue on 
MRI or CT. Only in 15 cases the PET/CT volume of PTV was 
smaller than in MRI. Finally the integrated MRI/PET/CT data 
increased PTV volume in 49 patients. The comparable PTV 
volumes were observed in 4 smallest non skull base 
meningiomas.  
Conclusions: Incorporation of (68)Ga-DOTATATE PET/CT 
improved the target volume delineation in meningiomas 
radiotherapy planning and gave additional clinical 
information in majority of patients in comparison with sole 
MRI/CT data. It is especially important in skull base 
meningiomas, post operation radiotherapy as well as for 
patients not qualified for MR exam. A determination of 
optimal threshold of SUV value for meningiomas needs 
further investigation. 
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For the majority of tumors, presence of distant metastases 
indicates incurable disease that must be treated with 
systemic means, usually with palliative intent. In a subset of 
patients with limited number of metastatic sites, usually 
from 1 to 5, (“oligometastatic disease”), there is emerging 
evidence that a curative intent approach can be associated 
with long-term survival. Most common forms of ablative 
therapy are surgical resection, stereotactic radiotherapy and 
radiofrequency ablation, all might differ in efficacy and 
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toxicity profiles depending on the size and location of 
metastatic sites. Clinical data indicate that the number of 
patients with oligometastatic disease receiving aggressive 
treatments is increasing rapidly. The distinct biological 
behavior of tumors with oligometastatic spread is currently 
explored by a number of groups. 
The most robust verification of ablative oligometastasis-
directed therapy has been documented in patients with 
limited intracranial metastases for which systemic treatment 
had limited efficacy. Randomized studies have demonstrated 
that surgical resection or radiosurgery can improve overall 
survival when added to whole-brain irradiation. Randomized 
evidence also exists for surgical resection of metastases, not 
solely in patients with oligometastases, causing epidural 
spinal cord compression. Outside of the central nervous 
system, limited randomized evidence exists to guide 
therapeutic decisions for patients with oligometastases. Most 
practice patterns are guided by large, single-institution or 
pooled series of patients demonstrating favorable survival. 
Limited number of studies with adequate controls raise the 
possibility that this survival gain might not be due to 
treatment effect, but rather due to patient selection 
criteria. For the widespread acceptance of oligometastatic 
ablative treatment, stronger evidence supporting its efficacy 
is needed. 
 
Oligo- and hypofractionated stereotactic radiotherapy of 
lung cancer 
R. Dziadziuszko 
Dept. of Oncology and Radiotherapy, Medical University of 
Gdańsk, Poland 
 
As a result of two decades of research, hypofractionated 
stereotactic radiotherapy of stage I non-small cell lung 
cancer (NSCLC) is now established as a standard of care in 
patients who are not candidates for surgical treatment. As 
demonstrated in large series of patients treated with SBRT 
for NSCLC, locoregional control exceeds 80% at 5-years, 
which appears comparable to surgical outcomes. SBRT 
programs became available in most European countries and 
centers, including several institutions in Poland. 
Implementation of successful SBRT program must focus on 
4D-CT imaging, co-registered with repeatable breath cycle, 
careful GTV and PTV delineation taking into account 
respiratory motion, treatment planning using advanced B-
type algorithms  by experienced physicists, image guided 
treatment delivery, and implementation of strict quality 
control measures. Most common treatment schedules include 
54Gy in 3 fractions, 55Gy in 5 fractions and 60Gy in 8 
fractions, depending on tumor location and proximity of 
organs-at-risk. Current research efforts exploring SBRT for 
lung cancer include clinical trials in patients who are 
considered for surgery, management of centrally located 
tumors, clinical and radiological patterns of disease 
recurrence, clinical and molecular prognostic factors and 
assessment of systemic therapies, including immunotherapies 
and targeted agents. Other studies evaluate the addition of 
SBRT as a boost to conventionally fractionated 
radiochemotherapy for stage II – III NSCLC. 
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Only relatively small proportion of hepatic tumors can be 
safely resected. Modern radiation treatment techniques can 
enhance, thus, therapeutic options beyond palliative 
systemic treatment or other local ablative techniques. The 
data from the literature indicate that stereotactic body 
radiation therapy (SBRT) can offer satisfactory rate of local 
control both in primary hepatocellular cancer (HCC) or liver 
metastases (LM). Total radiation dose  of 45 Gy or more and 
target diameter of less than 5 cm are among the factors 
related to favorable local control. Review of the published 
data indicate that local control at 1-2 years can, in general, 
exceed 70% in properly selected groups of patients. 
Respiratory motion of the liver provides a challenge in 
delivery of high radiation dose to the tumor demanding 
expansion of irradiated volume to encompass movements of 
the tumor. To address this problem special radiation 
techniques are used including respiratory gating, tracking or 
abdominal compression. Such techniques allow to minimize 
the margins and reduce, thus, the dose delivered to the 
normal tissue that surrounds the tumor. In spite of high local 
control rates overall survival of patients with hepatic tumors 
treated with SBRT is not satisfactory, mostly because of 
distant failures. This illustrates urgent need to develop new 
treatment strategies that would better integrate available 
local and systemic therapies. 
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Introduction: Prostate cancer (PC) is one of most common 
malignancies. Large percentage of PC patients is treated with 
radiotherapy (RT). The main problem connected to 
conventional radiotherapy is long overall treatment time 
(OTT) ranging to 8 weeks, so many attempts of OTT shrinkage 
are done. The one of them is CyberKnife based radioablation 
allowing to complete the therapy within 5-9 days. 
Material: 200 PC patients aged from 53 to 83 (mean 69)  
irradiated every other day using fd of 7.25 Gy to TD of 36.25 
Gy (OTT 9 days). 95 were from low risk, 104 from 
intermediate risk (excluding Gleason 4+3) and 1 from high 
risk group. The maximal PSA varied from 1.05 to 50.3 (mean 
8.6, median 7.6). T stage varied from T1c to T2c. Means of 
prostate dimensions before the treatment were 
42.5x37.5x40.4 mm for X, Y and Z axes respectively. 
Method: After treatment completion, 1, 4, 8 months later 
and next every each 6 months up to 26 months the 
percentage of patients using hormonal drugs (HT), GI (gastro-
intestinal) and GU (genito-urinary) toxicity using 
EORTC/RTOG scale (acute up to 4th month and next late) and 
PSA were checked. 
Results: Results obtained during FU are presented in the 
Table. 
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